Key developments

1. Jul 22, 2026

   Trinity Biotech partners with Latch Medical to integrate its CGM+ biosensor with an intradermal drug-delivery platform for metabolic conditions.

   7 sources on this →
2. Jul 22, 2026

   Trinity Biotech announces a 1-for-30 reverse ADS split to regain compliance with Nasdaq's $1 minimum bid price requirement.

   8 sources on this →

Coverage across the spectrum

Stories in this storyline

Photo: Ted Eytan / Wikimedia Commons (CC BY-SA 2.0)

Trinity Biotech, Latch Medical announce CGM+ drug-delivery partnership

Trinity Biotech and Latch Medical have announced a strategic collaboration to integrate Trinity’s AI-native CGM+ wearable biosensor with Latch’s Pharma Latch intradermal drug-delivery platform to guide precise injectable therapies for diabetes, obesity, and other metabolic conditions, aiming to create an AI-guided metabolic health platform. Trinity also plans a strategic equity investment in Latch as part of advancing regulatory-ready, biosensor-informed treatment approaches.

7 sources

Photo: Francisco Gonzalez / Wikimedia Commons (CC BY 2.0)

Trinity Biotech Plans 1-for-30 Reverse ADS Split to Meet Nasdaq

Trinity Biotech plans a 1-for-30 reverse ADS split, changing from 1 ADS for 20 Class A shares to 1 ADS for 600 Class A shares, to regain Nasdaq’s $1 minimum bid price and attract a broader investor base, with the move taking effect around July 24, 2026. The announcement followed by a dash in premarket trading and comes amid concerns over the company’s weak finances and profitability, which have kept the stock trading at depressed levels.